February 13, 2025

Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer

2 months ago talkbio0Tagged Clinical Trials, Gene Mutation, Inhibitor, Metastatic castration-resistant prostate cancer, Overall Survival, PARP1 gene, recombinational repair, TALAPRO-2, Talzenna, Xtandi

Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

Federal Judge Issues Nationwide Injunction on NIH Funding Cuts After Multi-State Lawsuit

2 months ago talkbio0Tagged Administration occupational activities, federal judge, Indirect, NIH Mouse, Research Projects, R-Series, Transitory, Transplant Registry Unified Management Program

NIH funding, research grants, federal judge, temporary restraining order, lawsuit, indirect costs, Trump administration

NIHs funding cut plan poses challenges for researchers despite court halt

2 months ago talkbio0Tagged Impact food supplement, Indirect, Legal, NIH Mouse, Research Projects, R-Series, Science

NIH funding cuts, indirect costs, research grants, legal challenges, scientific community impact

Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals

2 months ago talkbio0Tagged addiction, Alcohol Use Disorder, Craving for alcohol, Glucagon-Like Peptide 1, semaglutide, Wegovy, Weight Loss Medication

semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment

Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge

2 months ago talkbio0Tagged charge amounts, Clinical Trials, Escherichia coli, Failure (biologic function), Impaired, Johnson & Johnson, Phase 3, sanofi, Vaccines

Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

2 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

FDA Approves Evrysdi Tablets: A Breakthrough in Convenient SMA Treatment

2 months ago talkbio0Tagged Approved, Drug Formulation Process, Evrysdi, genentech, Oral treatment, Risdiplam, Roche (company), Spinal Muscular Atrophy, Tablet Dosage Form, United States Food and Drug Administration

Evrysdi, risdiplam, spinal muscular atrophy (SMA), FDA approval, tablet formulation, oral treatment, Genentech, Roche

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

2 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

2 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development